Trial Profile

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tilavonemab (Primary)
Indications Alzheimer's disease
Focus Adverse reactions
Sponsors AbbVie

Most Recent Events

25 Aug 2022 Status changed from completed to discontinued.
19 Jan 2022 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
15 Nov 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com